Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation

2003, Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, 101, 407, 10.1182/blood-2002-03-0993

2010, Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy, Transpl Infect Dis, 12, 322, 10.1111/j.1399-3062.2010.00504.x

2016, Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study, Lancet Haematol, 3, e119, 10.1016/S2352-3026(15)00289-6

2016, Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients, Open Forum Infect Dis, 3

1993, Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant, Ann Intern Med, 118, 173, 10.7326/0003-4819-118-3-199302010-00003

Maribavir 1263-300 Clinical Study Group, 2011, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, Lancet Infect Dis, 11, 284, 10.1016/S1473-3099(11)70024-X

2009, Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface, Bone Marrow Transplant, 44, 453, 10.1038/bmt.2009.254

2013, Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients, Clin Infect Dis, 57, 1550, 10.1093/cid/cit521

1993, Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial, Ann Intern Med, 118, 179, 10.7326/0003-4819-118-3-199302010-00004

2014, Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients, Clin Microbiol Infect, 20, 160, 10.1111/1469-0691.12222

2011, Complications, diagnosis, management, and prevention of CMV infections: current and future, Hematology Am Soc Hematol Educ Program, 2011, 305, 10.1182/asheducation-2011.1.305

2012, State-of-the-art monitoring of cytomegalovirus- specific cell-mediated immunity after organ transplant: a primer for the clinician, Clin Infect Dis, 55, 1678, 10.1093/cid/cis818

1994, Recovery of HLA-restricted cytomegalovirus (CMV)–specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis, Blood, 83, 1971, 10.1182/blood.V83.7.1971.1971

2007, Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation, Bone Marrow Transplant, 39, 293, 10.1038/sj.bmt.1705585

2013, Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation—a comparison of different assays for the detection of cytomegalovirus-specific T cells, Eur J Haematol, 91, 534, 10.1111/ejh.12187

2002, Definitions of cytomegalovirus infection and disease in transplant recipients, Clin Infect Dis, 34, 1094, 10.1086/339329

2007, Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV, Transpl Infect Dis, 9, 165, 10.1111/j.1399-3062.2006.00199.x

2008, Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation, J Virol, 82, 10143, 10.1128/JVI.00688-08

2005, Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease, J Exp Med, 201, 1999, 10.1084/jem.20042408

2012, Effect of two injections of non- adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial, Vaccine, 30, 7522, 10.1016/j.vaccine.2012.10.047

2011, SPICE: exploration and analysis of post- cytometric complex multivariate datasets, Cytometry A, 79, 167

2013, Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications, PLoS One, 8, e74744, 10.1371/journal.pone.0074744

1991, Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease, Blood, 78, 1373, 10.1182/blood.V78.5.1373.1373

2010, Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital, J Med Virol, 82, 433, 10.1002/jmv.21727

2016, Quantiferon CMV assay in allogenic stem cell transplant patients, J Clin Virol, 79, 10, 10.1016/j.jcv.2016.03.026

2009, Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients, Am J Transplant, 9, 1214, 10.1111/j.1600-6143.2009.02618.x

2008, Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity, Am J Transplant, 8, 1749, 10.1111/j.1600-6143.2008.02294.x

2013, Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study, Clin Infect Dis, 56, 817, 10.1093/cid/cis993

2012, Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia, Transplantation, 93, 195, 10.1097/TP.0b013e31823c1cd4

2009, Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection, J Virol, 83, 7649, 10.1128/JVI.00183-09

2008, T-cell quality in memory and protection: implications for vaccine design, Nat Rev Immunol, 8, 247, 10.1038/nri2274

2008, Phenotype and function of human T lymphocyte subsets: consensus and issues, Cytometry A, 73, 975

2006, HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells, Blood, 107, 4781, 10.1182/blood-2005-12-4818

2011, Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT, Bone Marrow Transplant, 46, 1089, 10.1038/bmt.2010.261

2001, Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes, J Immunol, 167, 181, 10.4049/jimmunol.167.1.181

2012, Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients, Clin Vaccine Immunol, 19, 791, 10.1128/CVI.05633-11

2006, Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients?, J Clin Virol, 35, 493, 10.1016/j.jcv.2005.10.017

2007, Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT, Bone Marrow Transplant, 40, 865, 10.1038/sj.bmt.1705825

2011, QuantiFERON-CMV assay for the assessment of cytomegalovirus cell-mediated immunity, Expert Rev Mol Diagn, 11, 17, 10.1586/erm.10.109

2009, Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT, Bone Marrow Transplant, 43, 853, 10.1038/bmt.2008.403

2014, Human cytomegalovirus (HCMV)–specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients, PLoS One, 9, e106044, 10.1371/journal.pone.0106044